NICEVIVA
MONOGRAPH SPEC LATEST 2026

Phenibut (Regulated)

SLEEP COGNITION · Evidence Monograph

Phenibut (Regulated) is an evidence-graded sleep cognition monograph evaluated across 30 peer-reviewed PubMed studies (2 meta-analyses, 2 systematic reviews, and 7 randomized controlled trials, encompassing n = 14,314 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 2 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 7 RCTs (0 Double-Blind)
Cumulative Participants n = 14,314
Reported Trial Dosages 400 g · 178.95 mg · 121.43 mg
Trial Duration Range 4 weeks · 18 months · 12 months
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (400 g · 178.95 mg · 121.43 mg) over a structured 4 weeks evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Clinically Standardized Formulation
Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.
Dose Adjustment Signal: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary sleep cognition clinical efficacy (30 PubMed studies)
Quantitative biomarker & outcome analysis (14 studies with effect-size/sample data)
Randomized controlled trial verification (7 RCTs · 0 double-blind)
Systematic review & meta-analysis synthesis (2 meta-analyses · 2 reviews)
01

What Is Phenibut (Regulated) & Why Does Form Matter?

Phenibut (Regulated) is classified under SLEEP COGNITION and has been investigated across 30 peer-reviewed PubMed publications for its role in targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (400 g, 178.95 mg, 121.43 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Phenibut (Regulated) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (7 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Phenibut (Regulated) acts on pathways governing targeted physiological homeostasis, clinical biomarker modulation, and evidence-based nutritional support. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Phenibut (Regulated) an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 2 meta-analyses, 2 systematic reviews, and 7 randomized controlled trials (0 double-blind, n = 14,314 total participants).

Representative peer-reviewed findings include: • PMID:42074316 (2026) — "The Role of Proinflammatory Cytokines in Temporomandibular Disorders: A Systematic Review." (An increased ratio of TNF to soluble TNF receptor in synovial fluid correlated with both pain and condylar damage, suggesting that loss of cytokine control contributes to progressive joint destruction.) • PMID:42033055 (2026) — "Physiological significance of autocrine orexinergic signaling in extra-hypothalamic tissues." (Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.) • PMID:42021548 (2026) — "Inhibition of Ferroptosis Alleviates Nanomaterial-Induced Toxicity: A Meta-Analysis of In Vitro and In Vivo Studies." (The protective mechanisms of Fer-1 or DFO included iron removal (showing reduced iron levels and down-regulated TFRC), anti-oxidation (manifested as inhibited formation of L-ROS, MDA, restoration of GSH, up-regulation of GPX4, down-regulation of ACSL4 and COX2) or anti-inflammati)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)RR Effect Size & 95% CI DistributionEstimate (95% CI)PMID 420542740.66 (0.46–0.96)PMID 420521020.66 (0.46–0.96)0.2Null (1)5Metric: RR
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Clinically Standardized Formulation. Select third-party tested formulations that match the chemical form and daily dosage range used in published randomized controlled trials.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 400 g · 178.95 mg · 121.43 mg over 4 weeks · 18 months · 12 months · 8 days. Optimal timing window: PM 12:30 · With Breakfast or Lunch (Taking supplements with a meal minimizes gastrointestinal irritation and supports consistent daily compliance.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Comfortable digestion and steady progress toward target clinical endpoints over 4–12 weeks.

Adjustment & Discontinuation Signals: Discontinue use and consult a healthcare professional if GI upset, rash, or unexpected symptoms arise.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Phenibut (Regulated), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · With Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (400 g · 178.95 mg · 121.43 mg) and re-evaluate efficacy after 4 weeks.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 14 Quantitative Analyses

01
SYSTEMATIC REVIEW International journal of molecular sciences (2026) PMID: 42074316 ↗
The Role of Proinflammatory Cytokines in Temporomandibular Disorders: A Systematic Review.
Clinical Trial Synthesis 2026 Systematic Review published in International journal of molecular sciences. Key conclusion: An increased ratio of TNF to soluble TNF receptor in synovial fluid correlated with both pain and condylar damage, suggesting that loss of cytokine control contributes to progressive joint destruction.
View Original PubMed Abstract ↓

Temporomandibular disorders (TMDs) are the prevalent causes of orofacial pain and dysfunction of the temporomandibular joint (TMJ) and masticatory muscles. Previous studies have revealed that proinflammatory cytokines play a key role in promoting inflammation, pain, and degeneration within the TMJ. In this context, the present systematic review synthesizes current evidence on various cytokines involved in the pathophysiology of TMDs and evaluates their associations with clinical signs and structural TMJ damage. A PRISMA-guided search (PROSPERO: CRD420251163290) was conducted in PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library to identify human-based, in vivo, and in vitro studies (January 2014 to September 2025) that assessed the roles of proinflammatory cytokines in TMDs. The following data were extracted from the identified studies: cytokine profiles, sampling methods, clinical outcomes, and TMJ structural changes. Study quality and risk of bias were systematically evaluated. A total of 15 studies (clinical, animal, and mechanistic) were included in the review. Tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-17 (IL-17) consistently emerged as the major contributors to synovitis, cartilage degradation, nociceptive sensitization, and bone resorption. Human studies showed that high levels of TNF-α, IL-1β, and IL-6 and chemokines such as C-C motif chemokine ligand 2 (CCL2) and regulated on activation, normal T-cell expressed and secreted (RANTES) were associated with TMJ pain, restricted mandibular motion, crepitus, malocclusion, and erosive changes on imaging. An increased ratio of TNF to soluble TNF receptor in synovial fluid correlated with both pain and condylar damage, suggesting that loss of cytokine control contributes to progressive joint destruction. TMDs, particularly inflammatory and degenerative subtypes, are cytokine-driven pathologies rather than purely mechanical disorders. TNF-α, IL-1β, and IL-6 are the promising candidate biomarkers of local inflammation and structural joint pathology. Standardized longitudinal studies are required to validate cytokine-based diagnostics and develop anti-cy

02
CLINICAL STUDY Physiological reports (2026) PMID: 42033055 ↗
Physiological significance of autocrine orexinergic signaling in extra-hypothalamic tissues.
Clinical Trial Synthesis 2026 Systematic Review published in Physiological reports. Key conclusion: Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
View Original PubMed Abstract ↓

Orexin-A and orexin-B, originally discovered as hypothalamic neuropeptides, have been detected in extra-hypothalamic tissues together with their receptors (OX1R and OX2R) since the early 2000s. This systematic review is the first to comprehensively synthesize evidence on the autocrine/paracrine effects of locally produced orexin across extra-hypothalamic tissues. Following PRISMA 2020 guidelines, a systematic search was conducted in PubMed, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, and Google Scholar. Eligible studies were original, full-text, peer-reviewed articles reporting primary data on prepro-orexin/orexin peptide and/or OX1R/OX2R expression in non-neuronal extra-hypothalamic tissues, with evidence of co-expression within the same cell/tissue or functional effects reasonably attributable to locally produced orexin. From the 10 eligible studies, autocrine orexinergic signaling was functionally demonstrated in the adrenal gland (steroidogenesis via Gq/PLC/IP3/Ca2+), male reproductive tract (testosterone secretion), adipose tissue (lipolysis/thermogenesis), heart (myocardial protection via PI3K/Akt/eNOS), pancreas (glucose-regulated insulin/glucagon modulation), and liver (lipogenesis via ERK1/2). OX1R primarily activates the Gq/PLC/IP3/Ca2+ pathway, resulting in ERK1/2 and p38 MAPK signaling (promoting secretion and proliferation), while OX2R couples to Gs/Gi, modulating cAMP and PI3K/Akt (favoring cytoprotection and anti-apoptosis). Autocrine orexinergic signaling constitutes a legitimate, compartment-autonomous regulatory mechanism in peripheral tissues, enabling rapid, tissue-specific responses insulated from central fluctuations. © 2026 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

03
META-ANALYSIS Journal of biochemical and molecular toxicology (2026) PMID: 42021548 ↗
Inhibition of Ferroptosis Alleviates Nanomaterial-Induced Toxicity: A Meta-Analysis of In Vitro and In Vivo Studies.
Clinical Trial Synthesis 2026 Meta-Analysis published in Journal of biochemical and molecular toxicology involving n = 51 participants (SMD 3.4). Key conclusion: The protective mechanisms of Fer-1 or DFO included iron removal (showing reduced iron levels and down-regulated TFRC), anti-oxidation (manifested as inhibited formation of L-ROS, MDA, restoration of GSH, up-regulation of GPX4, down-regulation of ACSL4 and COX2) or anti-inflammati
View Original PubMed Abstract ↓

Accumulating evidence supports ferroptosis as a key driver for nanomaterial (NM) exposure-induced toxicity. There is considerable interest in the therapeutic potential of ferroptosis inhibition for cells or animals exposed to NMs before clinical applications. This study aimed to synthesize data from published studies for achieving strong evidence about the effects of ferroptosis inhibitors. Fifty-three studies were included after searching PubMed, EMBASE and Cochrane Library databases up to October, 2025. The meta-analysis of in vitro studies (n = 51) showed treatment with ferroptosis inhibitors ferrostatin-1 (Fer-1; standardized mean difference [SMD] = 3.19; 95% confidence interval [CI] = 2.63-3.75) and deferoxamine (DFO; SMD = 3.40; 95% CI = 2.62-4.18) significantly improved the viability of cells exposed to NMs. The pooled results of in vivo studies (n = 8) demonstrated Fer-1 administration suppressed tissue cell death (SMD = -1.38; 95% CI = -2.39 to -0.37) and alleviated damages on the organ function [respiratory frequency (SMD = -1.33; 95% CI = -2.32 to -0.34); enhanced pause (SMD = -1.85; 95% CI = -2.95 to -0.75)] or the body weight (SMD = 1.28; 95% CI = 0.63-1.92) of animals exposed to NMs. The protective mechanisms of Fer-1 or DFO included iron removal (showing reduced iron levels and down-regulated TFRC), anti-oxidation (manifested as inhibited formation of L-ROS, MDA, restoration of GSH, up-regulation of GPX4, down-regulation of ACSL4 and COX2) or anti-inflammation (lowering IL-6, TNF-α and MCP-1). Accordingly, Fer-1 or DFO may be a potentially effective intervention for populations with NM exposure to prevent tissue damages. © 2026 Wiley Periodicals LLC.

04
CLINICAL STUDY Apoptosis (2026) PMID: 42008190 ↗
Necroptosis in pancreatic cancer: Molecular mechanisms and therapeutic implications.
Clinical Trial Synthesis 2026 Systematic Review published in Apoptosis. Key conclusion: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
View Original PubMed Abstract ↓

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer due to its strong resistance to chemotherapeutic agents that induce apoptosis. As conventional treatments gradually lose their effectiveness over time, necroptosis has become a key therapeutic target worth exploiting. Necroptosis is a regulated cell death independent of caspases. It is driven by the receptor-interacting protein kinase 1/3 (RIPK1/3) and mixed lineage kinase domain-like pseudokinase (MLKL) signaling axis. This systematic review summarizes the complex role of necroptosis in PDAC. We clarify how necroptosis can be triggered or manipulated pharmacologically, and how it can be induced by accumulating reactive oxygen species (ROS). We also critically analyze its tumor-promoting side. Persistent necroptotic signaling reshapes the tumor microenvironment (TME) by releasing damage-associated molecular patterns (DAMPs) and activating inflammatory cascades. We also highlight the growing clinical significance of necroptosis-related genes (NRGs), long non-coding RNAs (lncRNAs), and specific biomarkers such as fermitin family member 1 (FERMT1). Finally, we propose a new, context-dependent therapeutic framework. This framework proposes a combination of strategies for controlling necroptosis induction and immunomodulatory agents, offering a reasonable strategy for PDAC management. © 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

05
META-ANALYSIS Frontiers in psychology (2026) PMID: 41969889 ↗
Systematic review and meta-analysis of the impact of time management on college students' learning outcomes.
Clinical Trial Synthesis 2026 Meta-Analysis published in Frontiers in psychology involving n = 13,506 participants. Key conclusion: Moderation analysis revealed that both educational level and the time management measurement significantly moderate the relationship between time management and learning outcomes among college students.
View Original PubMed Abstract ↓

INTRODUCTION: Time management strategies are critical components of self-regulated learning and a key factor influencing learning outcomes. Although the application of time management strategies to learning behaviors has increased, their outcomes remains a subject of debate. Currently, there is a paucity of reliable, data-driven research conclusions on this topic. This study employed a meta-analytic approach to investigate the primary effect of time management on college students' learning outcomes, as well as five categories of moderating variables. METHODS: A meta-analysis was conducted on 31 studies published in both Chinese and English, utilizing CMA V3 software to analyze 33 aggregated independent samples (derived from 60 original effect sizes) derived from a total sample of 13,506 participants. RESULTS: The results indicate that time management is significantly and moderately positively correlated with college students' learning outcomes (r = 0.250). Moderation analysis revealed that both educational level and the time management measurement significantly moderate the relationship between time management and learning outcomes among college students. Specifically, time management strategies have the most pronounced effect on the learning outcomes of undergraduate students. Additionally, measurement instruments that assess time management abilities and behaviors more accurately capture the influence of time management on learning outcomes. DISCUSSION: These results have practical implications for designing interventions that directly support the growth of students' self-regulation capacities via structured time management training.

06
CLINICAL STUDY CNS neuroscience & therapeutics (2026) PMID: 41944596 ↗
Electroacupuncture Modulates Multiple Pathways for Neuroprotection and Neurorepair in Ischemic Stroke.
Clinical Trial Synthesis 2026 Clinical Study published in CNS neuroscience & therapeutics. Key conclusion: EA stands as a scientifically grounded, multi-target therapy improving stroke recovery.
View Original PubMed Abstract ↓

BACKGROUND: The complex pathophysiology of ischemic stroke (IS) involves initial injury followed by secondary cascades and endogenous repair. This review systematically explores how electroacupuncture (EA) precisely modulates these processes. METHODS: We systematically searched and summarized all papers related to EA treatment for stroke using the China National Knowledge Infrastructure (CNKI) and PubMed databases. RESULTS: We detail EA's key mechanisms in reducing initial and secondary damage, including the suppression of inflammatory responses (e.g., NF-κB, inflammasomes, gut-brain axis), mitigation of oxidative stress (Nrf2/HO-1), attenuation of excitotoxicity (NMDAR, GLT-1), and inhibition of diverse forms of regulated cell death (apoptosis, pyroptosis, ferroptosis). Critically, EA also actively promotes vital repair mechanisms by enhancing cerebral blood flow, protecting blood-brain barrier integrity, promoting angiogenesis (VEGF, HIF, Notch, Wnt pathways), and fostering extensive neural regeneration and plasticity (neurogenesis, neurotrophic factors, myelination, synaptic changes, network reorganization) at molecular, cellular, and network levels. These well-documented mechanistic actions provide a strong scientific basis for the observed clinical benefits of EA in improving major poststroke sequelae, encompassing motor, cognitive, language, and emotional deficits. CONCLUSIONS: The review highlights the potential for enhanced outcomes through combined therapy approaches and identifies future research avenues leveraging advanced technologies like multi-omics and AI for personalized precision EA. EA stands as a scientifically grounded, multi-target therapy improving stroke recovery. © 2026 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

07
SYSTEMATIC REVIEW Oncology research (2026) PMID: 41930142 ↗
Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects.
Clinical Trial Synthesis 2026 Systematic Review published in Oncology research. Key conclusion: CONCLUSIONS: Ferroptosis constitutes a promising therapeutic axis in SCLC.
View Original PubMed Abstract ↓

BACKGROUND: An increasing number of studies have shown that ferroptosis is related to the initiation and development of small cell lung cancer (SCLC). The systematic review aimed to summarize the characteristics of ferroptosis from its pathogenetic role to translational therapeutic implications in SCLC. METHODS: This systematic review, registered in PROSPERO (CRD420251090058), followed PRISMA 2020 guidelines. Comprehensive research of PubMed, Scopus, and Web of Science was performed for studies published between January 2010 and July 2025 investigating ferroptosis mechanisms, genetic or pharmacological modulation, or molecular profiling in SCLC. Two reviewers independently performed data extraction and quality assessment. RESULTS: Nineteen preclinical studies met the inclusion criteria. Key regulators included solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), ferroptosis suppressor protein 1 (FSP1), and acyl-CoA synthetase long chain family member 4 (ACSL4). The molecular subtypes of SCLC, achaete-scute homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and Yes1 associated transcriptional regulator (YAP1) exhibit differential ferroptosis gene expressions, influencing therapeutic responsiveness. Non-neuroendocrine subtypes are more ferroptosis-prone, whereas neuroendocrine variants display enhanced antioxidant defenses. Ferroptosis induction also promotes immune activation through stimulator of interferon genes (STING)-mediated CD8+ T-cell recruitment. CONCLUSIONS: Ferroptosis constitutes a promising therapeutic axis in SCLC. Integrating ferroptosis biomarkers into molecular stratification frameworks could refine patient selection and support precision oncology strategies, warranting further translational and clinical validation. © 2026 The Authors. Published by Tech Science Press.

08
CLINICAL STUDY Global change biology (2026) PMID: 41923349 ↗
Global Potential and Trade-Offs of Conservation Tillage for Crop Productivity and Ecosystem Services.
Clinical Trial Synthesis 2026 Meta-Analysis published in Global change biology. Key conclusion: Globally, CT reduced greenhouse gas (GHG) emissions by 5%, increased soil organic carbon sequestration by 21%, increased soil fertility by 11%, and reduced soil erosion by 12%, all while maintaining crop yields comparable to conventional tillage.
View Original PubMed Abstract ↓

Conservation Agriculture (CA) is pivotal to achieve sustainable intensification, yet the global efficacy of its core practice, conservation tillage (CT), remains debated regarding the trade-offs between crop productivity and ecosystem services across diverse environmental contexts. Here, we conducted a second-order meta-analysis, synthesizing 69 published meta-analyses, to elucidate the context-dependent drivers regulating the "win-win" outcomes of CT. Globally, CT reduced greenhouse gas (GHG) emissions by 5%, increased soil organic carbon sequestration by 21%, increased soil fertility by 11%, and reduced soil erosion by 12%, all while maintaining crop yields comparable to conventional tillage. However, CT can also emerge as a partial trade-off between crop yields and ecosystem services, notably between crop yield and GHG mitigation. These trade-offs were strongly regulated by climatic and edaphic conditions as well as management intensity. For instance, strong synergies between crop productivity and multiple ecosystem services were more pronounced in (semi-)arid regions characterized by low temperatures and low precipitation, as well as in coarse-textured alkaline soils. Furthermore, integrating CT with residue retention and crop rotations maximized these synergies, mitigating potential yield penalties. Collectively, our synthesis demonstrates that context-specific refinement of CT implementation is essential to reconcile agricultural productivity with ecosystem services, thereby advancing climate-resilient agricultural systems globally. © 2026 John Wiley & Sons Ltd.

09
CLINICAL STUDY Global change biology (2026) PMID: 41923270 ↗
Global Phosphorus Enrichment Reshapes Terrestrial Phosphorus Cycling.
Clinical Trial Synthesis 2026 Meta-Analysis published in Global change biology. Key conclusion: Our findings provide critical insights into the potential consequences of increasing anthropogenic P inputs in natural terrestrial ecosystems, improving our understanding of nutrient cycling and informing future ecosystem management under ongoing global change.
View Original PubMed Abstract ↓

Anthropogenic phosphorus (P) inputs are rapidly altering terrestrial P cycling through plant - soil - microbial interactions; however, global patterns and underlying mechanisms driving these changes remain poorly understood. By performing a global meta-analysis of 1315 observations from 176 studies across diverse natural terrestrial ecosystems, we found that P addition increased P concentrations in foliage, stems, roots, and litter by 62%, 114%, 100% and 63%, respectively. Soil total P, plant-available P, and microbial P concentrations rose by 43%, 221%, and 70%, while leaf P-resorption efficiency and soil phosphatase activity declined by 23% and 15%, respectively. Stem P and soil phosphatase activity exhibited consistent trends across tropical, temperate, and boreal zones, suggesting climate-specific P acquisition strategies. In addition, foliar P responses diverged among ecosystem and plant functional types. These responses were primarily regulated by background soil total P concentration, precipitation, soil pH, and P addition duration and rate. Our findings provide critical insights into the potential consequences of increasing anthropogenic P inputs in natural terrestrial ecosystems, improving our understanding of nutrient cycling and informing future ecosystem management under ongoing global change. © 2026 John Wiley & Sons Ltd.

10
CLINICAL STUDY Environmental pollution (Barking, Essex (2026) PMID: 41887349 ↗
From emission to toxicity: Unraveling the overlooked challenge of polycyclic aromatic hydrocarbons from vehicle exhaust.
Clinical Trial Synthesis 2026 Systematic Review published in Environmental pollution (Barking, Essex. Key conclusion: This review, from the dual perspectives of emissions and toxicity, systematically analyzed the emission characteristics and influencing factors of polycyclic aromatic hydrocarbons from vehicle sources, as well as the toxicity mechanism, provided ideas for the formulation of futur
View Original PubMed Abstract ↓

The polycyclic aromatic hydrocarbons present in vehicle exhaust, including both particulate and gaseous components, constitute a yet inadequately regulated threat to environmental health. However, there has been no systematic review on the emission characteristics and toxicity mechanism of polycyclic aromatic hydrocarbons in vehicle exhaust. Through comprehensive analysis, it was revealed that while high-ring particulate polycyclic aromatic hydrocarbons, especially Benzo[a]pyrene and Dibenz[a,h]anthracene, exhibit greater toxicity, the gaseous fraction of polycyclic aromatic hydrocarbons demonstrates higher emission levels and bioavailability, an aspect frequently underestimated in vehicle exhaust assessments. Meanwhile, engine type, emission standards, fuel type, driving conditions, and temperature largely affect the emission factors and compositional makeup of polycyclic aromatic hydrocarbons. This review, from the dual perspectives of emissions and toxicity, systematically analyzed the emission characteristics and influencing factors of polycyclic aromatic hydrocarbons from vehicle sources, as well as the toxicity mechanism, provided ideas for the formulation of future motor vehicle regulations that balance air quality improvement and public health protection, and also offered support for whether polycyclic aromatic hydrocarbons control should be included in future emission standards.

RELATED MONOGRAPHS

Related Monographs in This Category